MA33531B1 - Composés de benzoxazépine inhibiteurs de pi3k et leurs procédés d'utilisation - Google Patents

Composés de benzoxazépine inhibiteurs de pi3k et leurs procédés d'utilisation

Info

Publication number
MA33531B1
MA33531B1 MA34637A MA34637A MA33531B1 MA 33531 B1 MA33531 B1 MA 33531B1 MA 34637 A MA34637 A MA 34637A MA 34637 A MA34637 A MA 34637A MA 33531 B1 MA33531 B1 MA 33531B1
Authority
MA
Morocco
Prior art keywords
benzoxazepine
methods
pi3k inhibitors
formula
compounds
Prior art date
Application number
MA34637A
Other languages
Arabic (ar)
English (en)
Inventor
Nicole Blaquiere
Steven Do
Danette Dudley
Adrian J Folkes
Robert Heald
Timothy Heffron
Mark Jones
Aleksandr Kolesnikov
Chudi Ndubaku
Alan G Olivero
Stephen Price
Steven Staben
Lan Wang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43037239&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33531(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA33531B1 publication Critical patent/MA33531B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

L'INVENTION PORTE SUR DES COMPOSÉS DE BENZOXAZÉPINE DE FORMULE (I) Y COMPRIS LES STÉRÉOISOMÈRES, ISOMÈRES GÉOMÉTRIQUES, TAUTOMÈRES OU SELS PHARMACEUTIQUEMENT ACCEPTABLES DE CEUX-CI, DANS LAQUELLE FORMULE : Z1 REPRÉSENTE CR1 OU N; Z2 REPRÉSENTE CR2 OU N; Z3 REPRÉSENTE CR3 OU N; Z4 REPRÉSENTE CR4 OU N; ET B REPRÉSENTE UN NOYAU PYRAZOLYLE, IMIDAZOLYLE OU TRIAZOLYLE, LESQUELS COMPOSÉS ONT UNE ACTIVITÉ ANTICANCÉREUSE ET, PLUS SPÉCIFIQUEMENT, INHIBENT L'ACTIVITÉ DE LA PI3-KINASE.
MA34637A 2009-09-28 2012-02-15 Composés de benzoxazépine inhibiteurs de pi3k et leurs procédés d'utilisation MA33531B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24638109P 2009-09-28 2009-09-28
US33068510P 2010-05-03 2010-05-03
PCT/EP2010/064208 WO2011036280A1 (fr) 2009-09-28 2010-09-27 Composés de benzoxazépine inhibiteurs de pi3k et leurs procédés d'utilisation

Publications (1)

Publication Number Publication Date
MA33531B1 true MA33531B1 (fr) 2012-08-01

Family

ID=43037239

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34637A MA33531B1 (fr) 2009-09-28 2012-02-15 Composés de benzoxazépine inhibiteurs de pi3k et leurs procédés d'utilisation

Country Status (31)

Country Link
US (7) US8242104B2 (fr)
EP (3) EP2483278B1 (fr)
JP (2) JP5540101B2 (fr)
KR (1) KR101428346B1 (fr)
CN (2) CN102762576B (fr)
AR (1) AR078187A1 (fr)
AU (1) AU2010299816C1 (fr)
BR (1) BR112012006807A2 (fr)
CA (1) CA2772691C (fr)
CL (1) CL2012000754A1 (fr)
CO (1) CO6491026A2 (fr)
CR (1) CR20120121A (fr)
DK (1) DK2483278T3 (fr)
EC (1) ECSP12011755A (fr)
ES (2) ES2570569T3 (fr)
HR (1) HRP20140229T1 (fr)
IL (2) IL217558A (fr)
MA (1) MA33531B1 (fr)
MX (1) MX2012003591A (fr)
MY (2) MY160064A (fr)
NZ (1) NZ597833A (fr)
PE (1) PE20121025A1 (fr)
PL (1) PL2483278T3 (fr)
PT (1) PT2483278E (fr)
RS (1) RS53164B (fr)
RU (2) RU2654068C1 (fr)
SG (1) SG10201405049RA (fr)
SI (1) SI2483278T1 (fr)
TW (1) TWI423980B (fr)
WO (1) WO2011036280A1 (fr)
ZA (1) ZA201202199B (fr)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8952034B2 (en) 2009-07-27 2015-02-10 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
ES2558742T3 (es) 2009-09-28 2016-02-08 F. Hoffmann-La Roche Ag Compuestos inhibidores de PI3K de benzoxepina y métodos de uso
ES2570569T3 (es) * 2009-09-28 2016-05-19 Hoffmann La Roche Compuestos de benzoxazepina como inhibidores de la PI3K y métodos de uso
BR112012033402A2 (pt) 2010-07-02 2017-01-24 Gilead Sciences Inc moduladores de canais de íons conforme os compostos heterocíclicos fundidos
WO2012126901A1 (fr) * 2011-03-21 2012-09-27 F. Hoffmann-La Roche Ag Composés de benzoxazépine sélectifs pour pi3k p110 delta et leurs méthodes d'utilisation
CA2834164A1 (fr) 2011-05-10 2012-11-15 Gilead Sciences, Inc. Benzoxazinones fusionnees comme modulateurs de canal ionique
WO2012156379A1 (fr) 2011-05-13 2012-11-22 Universität Zürich Inhibiteurs de pik3/p110α pour la prévention de la resténose par application sous la forme d'un revêtement pour implant
TW201837023A (zh) 2011-07-01 2018-10-16 美商基利科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
NO3175985T3 (fr) 2011-07-01 2018-04-28
WO2013055874A2 (fr) 2011-10-14 2013-04-18 Genentech, Inc. Utilisations d'un article de manufacture comprenant du pertuzumab inhibiteur de dimérisation de her2 et article manufacture comprenant du pertuzumab inhibiteur de dimérisation de her2
JP2015507001A (ja) * 2012-02-17 2015-03-05 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 三環式化合物及びその使用方法
WO2013182668A1 (fr) * 2012-06-08 2013-12-12 F. Hoffmann-La Roche Ag Sélectivité mutante et associations d'un inhibiteur de phospho‑inositide 3 kinase et agents chimiothérapeutiques pour le traitement du cancer
JP6280546B2 (ja) 2012-06-26 2018-02-14 デル マー ファーマシューティカルズ ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法
CN102775395A (zh) * 2012-07-12 2012-11-14 江苏七洲绿色化工股份有限公司 一种丙环唑的制备方法及丙环唑中间体
IN2015DN00659A (fr) * 2012-08-07 2015-06-26 Janssen Pharmaceutica Nv
JP6363120B2 (ja) * 2013-03-13 2018-07-25 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ベンゾオキサゼピン化合物の作製方法
EP2983674A4 (fr) 2013-04-08 2017-05-10 Dennis M. Brown Bénéfice thérapeutique de composés chimiques administrés de façon sous-optimale
CN109293674A (zh) * 2013-12-16 2019-02-01 豪夫迈·罗氏有限公司 Gdc-0032的多晶型物、其制备方法和药物用途
JP2017507964A (ja) 2014-03-13 2017-03-23 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト エストロゲン受容体モジュレーターを用いた治療的組合せ
WO2016126726A1 (fr) 2015-02-02 2016-08-11 Forma Therapeutics, Inc. Acides hydroxamiques bicycliques [4,6,0] en tant qu'inhibiteurs hdac6
SG11201708622UA (en) 2015-02-02 2017-11-29 Forma Therapeutics Inc 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as hdac inhibitors
AR104068A1 (es) 2015-03-26 2017-06-21 Hoffmann La Roche Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer
CN107531721B (zh) * 2015-04-30 2020-07-17 诺华股份有限公司 用于调节法尼醇x受体的稠合的三环吡唑衍生物
AU2016278040B2 (en) 2015-06-16 2019-07-04 Nanophagix LLC Drug delivery and imaging chemical conjugate, formulations and methods of use thereof
HK1249866A1 (zh) 2015-06-29 2018-11-16 豪夫迈‧罗氏有限公司 用他塞利昔布进行治疗的方法
EP4212536B1 (fr) 2015-07-02 2025-02-19 F. Hoffmann-La Roche AG Composés de benzoxazepine oxazolidinone et procédés d'utilisation
WO2017001658A1 (fr) * 2015-07-02 2017-01-05 F. Hoffmann-La Roche Ag Composés de benzoxazépine oxazolidinone et leurs procédés d'utilisation
US10065970B2 (en) 2015-09-08 2018-09-04 Genentech, Inc. Tricyclic PI3K inhibitor compounds and methods of use
US9721369B2 (en) * 2015-09-15 2017-08-01 Facebook, Inc. Systems and methods for utilizing multiple map portions from multiple map data sources
EP3472131B1 (fr) 2016-06-17 2020-02-19 Forma Therapeutics, Inc. Acides hydroxamiques de 2-spiro-indan-5-yl ou de 2-spiro-indan-6-yl utilisés en tant qu'inhibiteurs de hdac
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
WO2018060091A1 (fr) 2016-09-29 2018-04-05 Bayer Cropscience Aktiengesellschaft Nouveaux dérivés d'imidazolylméthyle à substitution en position 5
TWI770093B (zh) * 2016-12-15 2022-07-11 瑞士商赫孚孟拉羅股份公司 製備苯并氧氮呯(benzoxazepin)噁唑啶酮化合物之方法
US11077189B2 (en) 2017-03-02 2021-08-03 Genentech Inc. Adjuvant treatment of HER2-positive breast cancer
MX394540B (es) 2017-04-28 2025-03-21 Hoffmann La Roche Polimorfos y formas solidas de la (s)-2-((2-((s)-4-(difluorometil)-2-oxooxazolidin-3-il)-5,6-dihidrobenzo[f]imidazo[1,2-d] [1,4]oxazepin-9-il)amino)propanamida, y metodos de produccion.
WO2019084459A1 (fr) * 2017-10-26 2019-05-02 Xynomic Pharmaceuticals, Inc. Sels et formes cristallines d'inhibiteur de la kinase b-raf
CA3101227A1 (fr) * 2018-05-30 2019-12-05 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Inhibiteur contenant un derive tricyclique, son procede de preparation et son application
CN111909157B (zh) 2019-05-07 2023-02-03 南京药石科技股份有限公司 Ezh2抑制剂及其用途
EP4056575A4 (fr) * 2019-11-04 2023-11-08 Betta Pharmaceuticals Co., Ltd Composé imidazolidinone, son procédé de préparation et son utilisation
WO2021088845A1 (fr) * 2019-11-04 2021-05-14 贝达药业股份有限公司 Composé imidazolidinone et son procédé de préparation et son utilisation
TWI886177B (zh) * 2019-11-25 2025-06-11 大陸商上海翰森生物醫藥科技有限公司 含三并環類衍生物的鹽或晶型及其醫藥組成物
CN117337290B (zh) * 2021-05-03 2026-01-02 轩竹生物科技股份有限公司 三并环类泛素特异性蛋白酶1抑制剂及其用途
JP2024520920A (ja) * 2021-05-13 2024-05-27 貝達薬業股▲ふん▼有限公司 イミダゾリジノン類化合物の多形体、調製方法及びその使用
AU2022282440A1 (en) 2021-05-28 2023-11-16 Genentech, Inc. Process for the preparation of benzoxazepin oxazolidinone compounds
WO2024104435A1 (fr) * 2022-11-17 2024-05-23 微境生物医药科技(上海)有限公司 INHIBITEUR DE PI3Kα TRICYCLIQUE, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION PHARMACEUTIQUE
CN116003280B (zh) * 2022-12-30 2024-11-19 合肥工业大学 一种芳基甲酰胺类化合物的光化学合成方法
WO2025082533A1 (fr) * 2023-10-21 2025-04-24 上海轶诺药业有限公司 Composés à cycle condensé, leur préparation et leur utilisation
WO2025237374A1 (fr) * 2024-05-16 2025-11-20 微境生物医药科技(上海)有限公司 Inhibiteur de pi3kalpha, son procédé de préparation et son utilisation pharmaceutique
WO2026027658A1 (fr) 2024-07-31 2026-02-05 Klostermeier Stefanie Inhibiteur de la phosphoinositide 3 kinase (pi3k) destiné à être utilisé dans le traitement de maladies neurologiques
EP4686476A1 (fr) 2024-07-31 2026-02-04 Klostermeier, Stefanie Inhibiteur de phosphoinositide 3 kinase (pi3k) destiné à être utilisé dans le traitement de maladies neurologiques

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
GB8504702D0 (en) * 1985-02-23 1985-03-27 Zyma Sa Tricyclic compounds
US5583024A (en) 1985-12-02 1996-12-10 The Regents Of The University Of California Recombinant expression of Coleoptera luciferase
FR2677356B1 (fr) * 1991-06-05 1995-03-17 Sanofi Sa Derives heterocycliques d'acylamino-2 thiazoles-5 substitues, leur preparation et compositions pharmaceutiques en contenant.
WO1994014777A1 (fr) * 1992-12-28 1994-07-07 Eisai Co., Ltd. Derives d'acide carbonique heterocyclique se fixant sur des recepteurs des retinoides
AU678503B2 (en) * 1993-09-24 1997-05-29 Takeda Chemical Industries Ltd. Condensed heterocyclic compounds and their use as squalene synthetase inhibitors
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
JPH08336393A (ja) 1995-04-13 1996-12-24 Mitsubishi Chem Corp 光学活性なγ−置換−β−ヒドロキシ酪酸エステルの製造法
US5985799A (en) * 1995-11-17 1999-11-16 E.I. Du Pont De Nemours And Company Tricyclic herbicidal heterocycles
US6602677B1 (en) 1997-09-19 2003-08-05 Promega Corporation Thermostable luciferases and methods of production
DE19908538A1 (de) * 1999-02-26 2000-08-31 Aventis Pharma Gmbh Polycyclische 2-Amino-Thiazol Systeme, Verfahren zu ihrer Herstellung und Arzneimittel enthaltend diese Verbindungen
DE19908535A1 (de) * 1999-02-26 2000-08-31 Aventis Pharma Gmbh Verwendung von polycyclischen Thiazol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
DE19908537A1 (de) * 1999-02-26 2000-08-31 Aventis Pharma Gmbh Verwendung von polycyclischen 2-Amino-Thiazol Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
DE19908533A1 (de) * 1999-02-26 2000-08-31 Aventis Pharma Gmbh Polycyclische Thiazol-Systeme, Verfahren zu ihrer Herstellung und Arzneimittel enthaltend diese Verbindungen
US7273880B2 (en) * 1999-06-30 2007-09-25 H. Lunbeck A/S Selective NPY (Y5) antagonists
AU2001246494A1 (en) 2000-03-03 2001-09-12 Novartis Ag Condensed thiazolamines and their use as neuropeptide y5 antagonists
RU2003126913A (ru) 2001-02-02 2005-03-10 Шеринг Корпорейшн (US) 3,4-дизамещенные циклобутен-1,2-дионы, как антагонисты хемокинового рецептора схс
TWI232863B (en) * 2001-06-11 2005-05-21 Akzo Nobel Nv Benzoxazepine derivatives
EP1530565A1 (fr) * 2002-07-19 2005-05-18 Pharmacia Corporation Composes de thiophene carboxamide substitues utilises pour traiter une inflammation
WO2004069245A1 (fr) * 2003-02-07 2004-08-19 Warner-Lambert Company Llc Derives d'oxazolidinones n-substitues par un noyau tricyclique, destines a etre utilises en tant qu'agents antibacteriens
TW200510356A (en) * 2003-08-01 2005-03-16 Takeda Chemical Industries Ltd Benzoxaepine compounds
US20050239767A1 (en) * 2003-10-28 2005-10-27 Chan Michael K Intermolecular SNAr of the heterocycle-activated nitro and fluoro groups-application in the synthesis of polyazamacrocyclic ligands
EP1765830B1 (fr) * 2004-07-01 2010-09-22 Merck Sharp & Dohme Corp. Inhibiteurs de la kinesine mitotique
KR20070064660A (ko) * 2004-10-07 2007-06-21 베링거 인겔하임 인터내셔날 게엠베하 Ｐｉ３ 키나제
HRP20110498T1 (hr) 2005-10-07 2011-08-31 Exelixis Azetidini kao inhibitori mek za liječenje proliferativnih bolesti
US20070238746A1 (en) * 2006-04-06 2007-10-11 Trixi Brandl Thiazolyl-dihydro-chinazoline
US20070238718A1 (en) * 2006-04-06 2007-10-11 Matthias Grauert Thiazolyl-dihydro-indazole
GB0610866D0 (en) * 2006-06-02 2006-07-12 Hammersmith Imanet Ltd Novel in vivo imaging compounds
CA2659280A1 (fr) * 2006-07-28 2008-01-31 Alcan Packaging Flexible France Film co-extrude avec de l'acide polylactique (pla) et un polymere ethylene/acetate de vinyle (eva)
ES2614931T3 (es) 2006-08-04 2017-06-02 Beth Israel Deaconess Medical Center Inhibidores de la piruvato cinasa y métodos de tratamiento de enfermedad
US8779154B2 (en) * 2006-09-26 2014-07-15 Qinglin Che Fused ring compounds for inflammation and immune-related uses
KR101578674B1 (ko) * 2006-12-29 2015-12-18 아비에 도이치란트 게엠베하 운트 콤파니 카게 카복스아미드 화합물 및 칼페인 억제제로서의 이의 용도
AU2008302703B2 (en) 2007-09-19 2013-11-07 The Regents Of The University Of California Positron emission tomography probes for imaging immune activation and selected cancers
ES2480994T3 (es) * 2008-03-31 2014-07-29 Genentech, Inc. Compuestos de tipo benzopirano y benzoxepina inhibidores de PI3K y métodos de uso
JP5579724B2 (ja) * 2008-10-17 2014-08-27 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ホスファチジルイノシトール−３−キナーゼ（ｐｉ−３キナーゼ）阻害剤としてのテトラ−アザ−複素環
ES2570569T3 (es) * 2009-09-28 2016-05-19 Hoffmann La Roche Compuestos de benzoxazepina como inhibidores de la PI3K y métodos de uso
ES2558742T3 (es) * 2009-09-28 2016-02-08 F. Hoffmann-La Roche Ag Compuestos inhibidores de PI3K de benzoxepina y métodos de uso

Also Published As

Publication number Publication date
US20160052933A1 (en) 2016-02-25
EP2483278B1 (fr) 2013-12-25
HK1211929A1 (en) 2016-06-03
EP2711368A1 (fr) 2014-03-26
HRP20140229T1 (hr) 2014-04-11
CN102762576B (zh) 2015-04-22
EP2483278A1 (fr) 2012-08-08
US9546178B2 (en) 2017-01-17
PT2483278E (pt) 2014-03-05
US20140058098A1 (en) 2014-02-27
TW201127844A (en) 2011-08-16
DK2483278T3 (da) 2014-01-13
SG10201405049RA (en) 2014-10-30
SI2483278T1 (sl) 2014-03-31
JP2014070075A (ja) 2014-04-21
CN102762576A (zh) 2012-10-31
US8785626B2 (en) 2014-07-22
US9198918B2 (en) 2015-12-01
RU2654068C1 (ru) 2018-05-16
CN104744491B (zh) 2017-07-11
MY160064A (en) 2017-02-15
RS53164B (sr) 2014-06-30
US20110076292A1 (en) 2011-03-31
CR20120121A (es) 2012-06-01
IL239081A0 (en) 2015-07-30
IL217558A0 (en) 2012-02-29
US20120244149A1 (en) 2012-09-27
NZ597833A (en) 2014-01-31
JP2013505917A (ja) 2013-02-21
US20170081341A1 (en) 2017-03-23
US8343955B2 (en) 2013-01-01
AU2010299816C1 (en) 2018-02-01
AR078187A1 (es) 2011-10-19
PE20121025A1 (es) 2012-08-06
JP5625101B2 (ja) 2014-11-12
ECSP12011755A (es) 2012-05-30
KR101428346B1 (ko) 2014-08-07
CA2772691A1 (fr) 2011-03-31
RU2012117398A (ru) 2013-11-10
AU2010299816A1 (en) 2012-02-02
ES2570569T3 (es) 2016-05-19
EP2845592A1 (fr) 2015-03-11
JP5540101B2 (ja) 2014-07-02
WO2011036280A1 (fr) 2011-03-31
MY184074A (en) 2021-03-17
US20130079331A1 (en) 2013-03-28
HK1174629A1 (en) 2013-06-14
KR20120065431A (ko) 2012-06-20
ZA201202199B (en) 2013-01-30
CN104744491A (zh) 2015-07-01
CO6491026A2 (es) 2012-07-31
US9670228B2 (en) 2017-06-06
PL2483278T3 (pl) 2014-05-30
TWI423980B (zh) 2014-01-21
US8586574B2 (en) 2013-11-19
EP2711368B1 (fr) 2016-03-23
IL239081B (en) 2018-05-31
CA2772691C (fr) 2017-10-03
MX2012003591A (es) 2012-04-19
CL2012000754A1 (es) 2012-09-07
AU2010299816B2 (en) 2015-11-12
US20140288047A1 (en) 2014-09-25
RU2600927C2 (ru) 2016-10-27
BR112012006807A2 (pt) 2020-11-03
US8242104B2 (en) 2012-08-14
ES2444779T3 (es) 2014-02-26
IL217558A (en) 2015-06-30

Similar Documents

Publication Publication Date Title
MA33531B1 (fr) Composés de benzoxazépine inhibiteurs de pi3k et leurs procédés d'utilisation
MA31358B1 (fr) Méthodes de traitement du cancer à l'aide d'inhibiteurs de pi3k alpha à base de pyridopyrimidinone
MA37142A3 (fr) Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine
MA31419B1 (fr) Derives de pyridine
TN2010000052A1 (fr) Derives de pyrazole et leur utilisation comme inhibiteurs de raf
MY157017A (en) Sulfonamide derivatives
MA32903B1 (fr) Inhibiteurs de proteine-kinases
MX2009009786A (es) Inhibidores de la via de hedgehog.
TN2009000329A1 (fr) DERIVES DE 2-AMINO-5,7-DIHYDRO-6H-PYRROLO[3,4-d]-PYRIMIDINE SERVANT D'INHBITEURS DE HSP-90 POUR LE TRAITEMENT DU CANCER
SMT201300109B (it) Imidazopiridazincarbonitrili utili come inibitori di chinasi
HRP20040686B1 (hr) Novi heterocikliäśki spojevi koji djeluju kao inhibitori beta-laktamaza
MA35024B1 (fr) Dérivés de pyrrolo-[2,3-d]pyrimidine servant d'inhibiteurs des kinases apparentés à la tropomyosine
TN2012000062A1 (en) Jak 2 inhibitors and their use for the treatment of myeloproliferative deseases and cancer
MA32904B1 (fr) Composes de purine
MA37866B1 (fr) Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur
NI200900183A (es) Compuestos de pirido [2,3-d] pirimidina - 7 - ona como inhibidores de pi3k - alfa para el tratamiento del cáncer.
MA34760B1 (fr) Composés et leurs utilisation
WO2008079873A3 (fr) Utilisation de composés thiazolyle comme inhibiteurs de kinases
WO2011041304A3 (fr) Agents antipaludiques inhibiteurs de la dihydro-orotate déshydrogénase
EA201991916A1 (ru) 1,4,6-ТРИЗАМЕЩЕННЫЕ-2-АЛКИЛ-1H-БЕНЗО[d]ИМИДАЗОЛЬНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ДИГИДРООРОТАТНЫХ ОКСИГЕНАЗНЫХ ИНГИБИТОРОВ
MA40250A (fr) Dérivés de quinolizinone utilisés comme inhibiteurs de pi3k
NZ592927A (en) PHOSPHODIESTERASE TYPE III (PDE III) INHIBITORS OR CA2+-SENSITIZING AGENTS such as pimobendan FOR THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY
TN2016000253A1 (en) [1,2,4]triazolo[1,5-a]pyrimidine derivatives as protozoan proteasome inhibitors for the treatment of parasitic diseases such as leishmaniasis.
UY31824A (es) Nuevos compuestos
MA35010B1 (fr) Inhibiteurs de la peptide déformylase